Durango SC, Martínez SLM, Vásquez EV, Senior BPA, Senior BJD, Senior SJM, Saavedra VME, García OS

Language: Spanish
References: 21
Page: 574-580
PDF size: 330.01 Kb.

ABSTRACT

Objective: To stratify the likelihood of developing heparin-induced thrombocytopenia by implementing the 4-T score in hospitalized patients who have presented with thrombocytopenia during heparin administration.
Materials and Methods: A retrospective, descriptive, observational study including hospitalized adult patients who had received heparin treatment and subsequently developed thrombocytopenia. Non-probability sampling of consecutive cases and univariate analysis were performed.
Results: Twenty-four patients were included, median age was 65.5 years and male sex was the most prevalent (14/24 patients). Cardiovascular causes were the most frequent reason for hospitalization; the median hospitalization time was 12.5 days; 17 patients had no history of thrombotic events prior to the administration. A risk factor associated with thrombotic symptoms was stroke in 3 patients, and 22 had no previous exposure to heparin.
Conclusions: Heparin-induced thrombocytopenia is a potentially serious adverse event that requires strict follow-up by medical personnel. In this study, this adverse effect was frequently found in patients with thromboprophylaxis for a related cardiovascular disease, among which acute myocardial infarction predominated.

REFERENCES

1. Vera O. Farmacología básica y clínica de los anticoagulantes.Revista Cuadernos 2022; 63 (1): 55-63.

2. Casu B, Naggi A, Torri G. Re-visiting the structure ofheparin. Carbohydr Res 2015; 403: 60-8. doi: 10.1016/j.carres.2014.06.023

3. Hemker HC. A century of heparin: past, present and future.J Thromb Haemost 2016; 14 (12): 2329-2338. doi:10.1111/jth.13555

4. Cruz I, Sánchez M, Sánchez PL, Jang IK. Trombocitopeniainducida por heparina [Heparin-induced thrombocytopenia].Rev Esp Cardiol 2007; 60 (10): 1071-82. doi:10.1157/13111239

5. Martinuzzo ME, Cerrato GS, Iglesias Varela ML, AdamczukYP, et al. Los niveles de anticuerpos anti factor plaquetario4-heparina y el índice 4T para trombocitopenia inducidapor heparina [Levels of antiplatelet factor 4-heparin antibodiesand 4T score for heparin induced thrombocytopenia].Medicina (B Aires) 2012; 72 (1): 19-22.

6. McGowan K, Makari J, Diamantouros A, Bucci C, et al. Reducingthe hospital burden of heparin-induced thrombocytopenia:impact of an avoid-heparin program. Blood 2016;127 (16): 1954-9. doi: 10.1182/blood-2015-07-660001

7. Zehnder T, Zeller A. CME: Heparin-induzierte Thrombozytopenie[CME: Heparin-induced thrombocytopenia]. Praxis(Bern 1994) 2020; 109 (2): 65-70. doi: 10.1024/1661-8157/a003365

8. Nagler M, Bachmann L, Cate H, Cate-Hoek A. Diagnosticvalue of immunoassays for heparin-induced thrombocytopenia:a systematic review and meta-analysis.Blood 2016; 127 (5): 546-57. https://doi.org/10.1182/blood-2015-07-661215

9. Rostami M, Mansouritorghabeh H. Significance of heparininduced thrombocytopenia (HIT) in COVID-19: a systematicreview and meta-analysis. J Thromb Thrombolysis 2023:1-12. doi: 10.1007/s11239-023-02827-5

10. Lo GK, Juhl D, Warkentin TE, Sigouin CS, et al. Evaluationof pretest clinical score (4 T's) for the diagnosis of heparininducedthrombocytopenia in two clinical settings. JThromb Haemost 2006; 4 (4): 759-65. doi: 10.1111/j.1538-7836.2006.01787.x

11. Li S, Fan LK, Wang SJ, Zhao YQ. Prospective evaluation ofheparin-induced thrombocytopenia expert probabilityand 4T scores in Chinese patients with suspected heparininduced thrombocytopenia. Chin Med J (Engl) 2019; 132(12): 1441-7. doi: 10.1097/CM9.0000000000000261

12. Páramo JA, Lozano ML, González-Porras JR, Mateo J. Currentstatus of diagnosis and treatment of heparin-inducedthrombocytopenia (HIT). Med Clin (Barc) 2022; 158 (2):82-9. doi: 10.1016/j.medcli.2021.05.020

13. Warkentin TE. Heparin-induced thrombocytopenia. En:Elsevier. Hematology: Basic Principles and Practice. 7thedition. Philadelphia: Elsevier; 2018: 1973-83.

14. Cios T, Salamanca-Padilla Y, Guvakov D. An anti-coagulationconundrum: implantation of total artificial heartin a patient with heparin-induced thrombocytopeniatype II. Am J Case Rep 2017; 18: 294-8. doi: 10.12659/ajcr.902320

15. Khandelwal S, Lee G, Hester C, Poncz M, et al. The antigeniccomplex in HIT binds to B cells via complement and complementreceptor 2 (CD21). Blood 2016; 128 (14): 1789-1799.doi: 10.1182/blood-2016-04-709634

16. Hogan M, Berger JS. Heparin-induced thrombocytopenia(HIT): Review of incidence, diagnosis, andmanagement. Vasc Med 2020; 25 (2): 160-73. doi:10.1177/1358863X19898253

17. Cegarra-Sanmartín V, et al. Fondaparinux como alternativasegura para el manejo de la trombocitopenia inducida porheparina en pacientes postoperatorios de cirugía cardiaca.Revista de Anestesia Cardiotorácica y Vascular 2014; 28(4): 1008-12. https://doi.org/10.1053/j.jvca.2013.09.008

18. Sullivan J, Bak E, Sullivan MJ, Gurnani PK. Predictivevalue of scoring tools in determining heparin-inducedthrombocytopenia in patients on extracorporeal membraneoxygenation. Perfusion 2020; 35 (5): 378-83. doi:10.1177/0267659119881266

19. Larsen EL, Nilius H, Studt JD, Tsakiris DA, et al. Accuracyof diagnosing heparin-induced thrombocytopenia. JAMANetw Open 2024; 7 (3): e243786. doi: 10.1001/jamanetworkopen.

20. 2024.378620. Hogan M, Berger JS. Heparin-induced thrombocytopenia(HIT): Review of incidence, diagnosis, andmanagement. Vasc Med 2020; 25 (2): 160-73. doi:10.1177/1358863X19898253

21. Liu L, Zheng H, Chen S, Wang S, Yang M. Heparin-inducedthrombocytopenia associated with low-molecular-weightheparin: clinical feature analysis of cases and pharmacovigilanceassessment of the FAERS database. Front Pharmacol2023; 14: 1247253. doi: 10.3389/fphar.2023.1247253